Search by Drug Name or NDC
NDC 00781-6022-46 Clarithromycin 125 mg/5mL Details
Clarithromycin 125 mg/5mL
Clarithromycin is a ORAL FOR SUSPENSION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Sandoz Inc. The primary component is CLARITHROMYCIN.
MedlinePlus Drug Summary
Clarithromycin is used to treat certain bacterial infections, such as pneumonia (a lung infection), bronchitis (infection of the tubes leading to the lungs), and infections of the ears, sinuses, skin, and throat. It also is used to treat and prevent disseminated Mycobacterium avium complex (MAC) infection [a type of lung infection that often affects people with human immunodeficiency virus (HIV)]. It is used in combination with other medications to eliminate H. pylori, a bacterium that causes ulcers. Clarithromycin is in a class of medications called macrolide antibiotics. It works by stopping the growth of bacteria. Antibiotics such as clarithromycin will not work for colds, flu, or other viral infections. Taking antibiotics when they are not needed increases your risk of getting an infection later that resists antibiotic treatment.
Related Packages: 00781-6022-46Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Clarithromycin
Product Information
| NDC | 00781-6022 |
|---|---|
| Product ID | 0781-6022_fcbab0c3-9fdb-40aa-9a17-e53f88a19bbc |
| Associated GPIs | 03500010001910 |
| GCN Sequence Number | 019146 |
| GCN Sequence Number Description | clarithromycin SUSP RECON 125 MG/5ML ORAL |
| HIC3 | W1D |
| HIC3 Description | MACROLIDE ANTIBIOTICS |
| GCN | 11670 |
| HICL Sequence Number | 006228 |
| HICL Sequence Number Description | CLARITHROMYCIN |
| Brand/Generic | Generic |
| Proprietary Name | Clarithromycin |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Clarithromycin |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | FOR SUSPENSION |
| Route | ORAL |
| Active Ingredient Strength | 125 |
| Active Ingredient Units | mg/5mL |
| Substance Name | CLARITHROMYCIN |
| Labeler Name | Sandoz Inc |
| Pharmaceutical Class | Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Macrolide Antimicrobial [EPC], Macrolides [CS], P-Glycoprotein Inhibitors [MoA] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA065283 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00781-6022-46 (00781602246)
| NDC Package Code | 0781-6022-46 |
|---|---|
| Billing NDC | 00781602246 |
| Package | 100 mL in 1 BOTTLE (0781-6022-46) |
| Marketing Start Date | 2007-09-04 |
| NDC Exclude Flag | N |
| Pricing Information | |
| Price Per Unit | 0.8604 |
| Pricing Unit | ML |
| Effective Date | 2023-01-18 |
| NDC Description | CLARITHROMYCIN 125 MG/5 ML SUS |
| Pharmacy Type Indicator | C/I |
| OTC | N |
| Explanation Code | 4, 5 |
| Classification for Rate Setting | G |
| As of Date | 2024-01-10 |